StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Care sales

<< Previous

Bullboard Posts

Next >>

Comment by Skrit37on Mar 18, 2022 4:08pm

98 Views

Post# 34526579

RE:RE:Care sales

Well done lithlover, you make it to easy for those who don't like homework haha

LithLover wrote: From the News release of Aug 16, 2021:

TORONTO, ON / ACCESSWIRE / August 16, 2021 / StageZero Life Sciences, Ltd (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), a healthcare company working to reduce the risk of cancer and other chronic diseases through early detection and intervention, today announced the signing of a share purchase agreement (the "Definitive Agreement") to acquire all of the shares of Clinics Operations Limited, a provider of specialist clinical services across Europe and North America, and wholly owned subsidiary of Health Clinics Limited (the "Acquisition").

Transaction Highlights

Adds ~$4 million in annual revenue and is immediately accretive to StageZero

Provides StageZero Life Sciences with full access to Care Oncology's network of oncologists and physicians across the United States, including Care Oncology's Los Angeles clinic, and the physicians' healthcare affiliations.

Positions StageZero to take full advantage of the multi-billion dollar emerging global market for liquid biopsy diagnostic tools and the strong trend toward telehealth and early-disease diagnostics

Adds experienced management expertise to build out StageZero's clinical offerings and significantly expands the sales and marketing effort.

Offers synergistic cross-selling opportunities as StageZero provides diagnostic tests to the thousands of current Care Oncology patients, with StageZero liquid diagnostic customers now having access to the full Care Oncology "Patient Journey". This, in turn, provides multiple revenue streams.

From the News release of Sept 2, 2021:

TORONTO, ON / ACCESSWIRE / September 2, 2021 / StageZero Life Sciences, Ltd (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), a healthcare company working to reduce the risk of cancer and other chronic diseases through early detection and intervention, today announced that it has completed its previously announced acquisition of the business of Health Clinics Limited (the "Acquisition"). The Acquisition was completed through the acquisition of all of the shares of Clinics Operations Limited, a provider of specialist clinical services across Europe and North America, and a wholly-owned subsidiary of Health Clinics Limited, and the acquisition of substantially all of the assets of Health Clinics USA, Corp. ("HC USA"), a company in which Health Clinics Limited holds significant ownership interest.

From the Interim Financials of Nov 15, 2021 posted on Sedar. Page 31:

Revenue for three month ending Sept 30, 2021:
Clinical Consultation $273,398

Deferred Revenue for three month ending Sept 30, 2021:
Clinical Consultation $115,982

Total of $389,380. The acquistion was finalized on Sept 2, 2021, Q3 is July-Sept so this would represent only 1 month of revenue for Clinical Consultation. There was no revenue amount listed under Clinical Consultation prior to Q3, 2021.

brad129 wrote: Where did we get the numbers for Care that prior to acquisition they were doing 1 million per quarter? If correct than we should see minimum 1 million on the books since we have had a full quarter of sales.